‘Empty shelves’: Pharmacies flag cold and flu med supply issues as demand spikes

Pharmacists have reported struggling to get hold of medicines such as Lemsip amid a significant increase in demand for cold and flu treatments.

Some pharmacists reported they had "sold out of all cold remedies"

Community pharmacists and the public have taken to social media over the last few days to warn of difficulties accessing the medicines.

One contractor said they “can’t get basics” such as Night Nurse and Lemsip, while Bexley, Bromley and Greenwich local pharmaceutical committee said pharmacies were “sold out of all cold remedies” over Christmas.

Lemsip's manufacturer Reckitt told C+D it is doing its best to "minimise disruption" to customers amid surging demand for the product. C+D has also contacted Night Nurse's manufacturer Haleon for comment.

Meanwhile, Association of Independent Multiple pharmacies CEO Leyla Hannbeck highlighted “empty shelves in pharmacies” as “supply is struggling to meet the demand” for common flu medicines.

She said: “The medicines supply concerns continue.

“For months we’ve asked [the Department of Health and Social Care] to hold stakeholder discussions to suggest solutions and plan better, but no action yet. Why?” 

And a Boots spokesperson admitted to C+D that some of its branches may face “temporary shortages” of Lemsip.

They told C+D: “We have seen higher than usual demand for Lemsip. There is still availability in many of our stores, and although there may be temporary shortages in some, there will normally be suitable alternatives available.

“If in doubt, customers should speak to their pharmacist for advice on alternatives.”

The spokesperson added that customers can “check product availability at stores near them” via the multiple’s website.

“We also encourage people to minimise the risk of winter viruses by making sure they have had their flu jab and COVID-19 booster, if eligible,” they said.

C+D also approached Lloydspharmacy, Tesco, Asda, Rowlands and Superdrug for comment.

Lemsip manufacturer “doing all we can”

Lemsip manufacturer Reckitt told C+D it is “seeing significantly increased demand” and is “doing all [it] can”.

A spokesperson said: “We are seeing significantly increased demand during the current cold and flu season. We are doing all we can to minimise disruption to our customers and consumers.”

COVID-19 and flu “twindemic”

It comes as NHS England has warned that its fears of a COVID-19 and flu “twindemic” have “been realised”.

Official data released on Friday (December 30) revealed that cases of flu in hospital are now more than seven times higher than last month.

It showed there were 3,746 patients a day in hospital with flu the previous week, compared with 520 the previous month and only 34 patients in hospital with flu at the same time last year.

NHS national medical director Professor Sir Stephen Powis said: “Sadly, these latest flu numbers show our fears of a ‘twindemic’ have been realised, with cases up seven-fold in just a month and the continued impact of COVID-19 hitting staff hard, with related absences up almost 50% on the end of November.”

Meanwhile, pharmacists have also faced struggles with mounting demand for antibiotics used to treat strep A, with the government issuing eight serious shortage protocols allowing pharmacists to supply alternative penicillin medicines last month.

Sign in or register for free

Costanza Potter

Read more by Costanza Potter

Cos Potter joined C+D as its news editor in December 2022 but has been covering primary care news for over five years. After starting out at the pharmacy press in 2019, she worked at a GP title for several years before the pharmacy sector beckoned her back.

Latest from News

Superdrug rolls out at-home cardiovascular disease test

 
• By 
 • comment0

Superdrug has partnered with PocDoc to introduce an “at-home” cardiovascular disease (CVD) test both online and in-store in over 180 pharmacies across the UK.

Pharmacies face ‘huge’ losses amid NMS subcontracting ban

 
• By 
 • comment5

Small independent pharmacies are facing a financial hit of thousands of pounds per month after reforms banning NMS subcontracting, C+D has learned.

WBA agrees ‘landmark’ $300m settlement over ‘invalid’ scripts

 
• By 
 • comment0

Boots’ parent company will pay at least $300m to the US government to “resolve allegations” it filled millions of unlawful opioid and controlled substance prescriptions from 2012 to 2023.

More from Clinical

Slew of fentanyl patches ‘out of stock’ until December

 
• By 
 • comment1

The government has issued a warning that multiple strengths of fentanyl delivered through transdermal patches will be out of stock until the end of the year.

RSV jab pilot to expand by ‘up to’ 200 pharmacies

 
• By 
 • comment0

The DH has revealed plans to expand the pharmacy RSV vaccine programme by “up to 200 sites in identified target areas” in 2025/26 to “reverse the downward trend” in uptake.